In this Product Explainer, Infectious Disease Physician and Microbiologist Prof Paul Griffin explains the role of a recombinant respiratory syncytial virus pre-fusion F protein vaccine for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).

Additional resources

• NCIRS FAQ: Respiratory syncytial virus (RSV) FAQs | NCIRS.
• NCIRS Fact Sheet – state funding of Nirsevimab, eligibility criteria by state: State and territory nirsevimab program summary 2025.pdf